321 related articles for article (PubMed ID: 19318477)
1. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.
Klein O; Ebert LM; Nicholaou T; Browning J; Russell SE; Zuber M; Jackson HM; Dimopoulos N; Tan BS; Hoos A; Luescher IF; Davis ID; Chen W; Cebon J
Clin Cancer Res; 2009 Apr; 15(7):2507-13. PubMed ID: 19318477
[TBL] [Abstract][Full Text] [Related]
2. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.
Weber JS; Hamid O; Chasalow SD; Wu DY; Parker SM; Galbraith S; Gnjatic S; Berman D
J Immunother; 2012 Jan; 35(1):89-97. PubMed ID: 22130166
[TBL] [Abstract][Full Text] [Related]
5. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
[TBL] [Abstract][Full Text] [Related]
6. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
[TBL] [Abstract][Full Text] [Related]
7. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides.
Jäger E; Maeurer M; Höhn H; Karbach J; Jäger D; Zidianakis Z; Bakhshandeh-Bath A; Orth J; Neukirch C; Necker A; Reichert TE; Knuth A
Int J Cancer; 2000 May; 86(4):538-47. PubMed ID: 10797269
[TBL] [Abstract][Full Text] [Related]
8. Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: autoimmune nature of the anti-melanoma CTL response.
Tsomides TJ; Reilly EB; Eisen HN
Int Immunol; 1997 Feb; 9(2):327-38. PubMed ID: 9040014
[TBL] [Abstract][Full Text] [Related]
9. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
Valmori D; Gervois N; Rimoldi D; Fonteneau JF; Bonelo A; Liénard D; Rivoltini L; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Dec; 161(12):6956-62. PubMed ID: 9862730
[TBL] [Abstract][Full Text] [Related]
10. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.
Appay V; Voelter V; Rufer N; Reynard S; Jandus C; Gasparini D; Lienard D; Speiser DE; Schneider P; Cerottini JC; Romero P; Leyvraz S
J Immunother; 2007; 30(2):240-50. PubMed ID: 17471171
[TBL] [Abstract][Full Text] [Related]
11. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
12. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy).
Bakacs T; Mehrishi JN; Szabó M; Moss RW
Pharmacol Res; 2012 Aug; 66(2):192-7. PubMed ID: 22503629
[TBL] [Abstract][Full Text] [Related]
13. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
14. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones.
Khammari A; Labarrière N; Vignard V; Nguyen JM; Pandolfino MC; Knol AC; Quéreux G; Saiagh S; Brocard A; Jotereau F; Dreno B
J Invest Dermatol; 2009 Dec; 129(12):2835-42. PubMed ID: 19554023
[TBL] [Abstract][Full Text] [Related]
16. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
Valmori D; Fonteneau JF; Lizana CM; Gervois N; Liénard D; Rimoldi D; Jongeneel V; Jotereau F; Cerottini JC; Romero P
J Immunol; 1998 Feb; 160(4):1750-8. PubMed ID: 9469433
[TBL] [Abstract][Full Text] [Related]
17. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response.
Dunbar PR; Smith CL; Chao D; Salio M; Shepherd D; Mirza F; Lipp M; Lanzavecchia A; Sallusto F; Evans A; Russell-Jones R; Harris AL; Cerundolo V
J Immunol; 2000 Dec; 165(11):6644-52. PubMed ID: 11086110
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes.
Adamina M; Bolli M; Albo F; Cavazza A; Zajac P; Padovan E; Schumacher R; Reschner A; Feder C; Marti WR; Oertli D; Heberer M; Spagnoli GC
Br J Cancer; 2004 Jan; 90(1):263-9. PubMed ID: 14710238
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
